News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Baxter International, Inc. (BAX) Completes CE Mark Approval For VIVIA Hemodialysis System In Europe



12/20/2013 9:30:13 AM

free biotech news Get the latest biotech news where you want it. Sign up for the free GenePool newsletter today!

DEERFIELD, Ill.--(BUSINESS WIRE)--Baxter International Inc. (NYSE:BAX) today announced completion of CE marking in Europe for the VIVIA hemodialysis (HD) system, designed to deliver more frequent, extended duration, short daily or nocturnal home HD therapy, known as High Dose HD therapy1. ''Globally, less than 1 percent of the estimated 1.9 million patients requiring hemodialysis currently perform High Dose HD therapy,'' said Bruce Culleton, M.D., senior medical director, Baxter. ''VIVIA will allow a greater number of hemodialysis patients access to High Dose HD therapy in their home environment.''

Help employers find you! Check out all the jobs and post your resume.

Read at BioSpace.com


comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES